ABOUT ENTEGRIS

In biopharmaceutical production, each instance where materials or products in development must be stored, handled, or transported presents a risk for breakage, contamination, and expensive product loss. In a modern, decentralized biopharmaceutical production line, materials and products must be kept frozen to ensure product safety, consistency, and shelf life. Because of these new realities, we face more production costs, logistics, speed, and complexity.

Bioproduction today has dramatically increased the value of product in each container. Production processes have been contracted out or may be taking place in different parts of the country or globe. At colder temperatures, containers have considerable limitations; traditional storage bottles are often more brittle at cold temperatures and can break easily, do not pack into containers or store in freezers efficiently and take longer to freeze and thaw due to their shape and volume. 

Entegris is in a unique position to help overcome these cold temperature challenges by offering assemblies designed for extreme cold and by partnering with qualified equipment manufacturers specializing in reliable, cold-chain containment. Let us help you gain control over your processes and reduce the potentially enormous financial risk to your valuable products. 

DATASHEETS

The utilization of single-use (SU) systems continues to grow, and so do the purity concerns of the SU components and their potential impact on high-value final products. From the high cost of product loss due to assembly failures at fill/finish, to the ever-increasing scrutiny from regulatory bodies, every angle requires protective measures. Now, Entegris brings a new level of assurance to your process. The Aramus™ single-use 2D bags are made of a high-grade, gamma-stable fluoropolymer, providing higher purity, greater compatibility, and increased safety for critical process fluids and final products.

Two of the most significant benefits to single-use bioprocessing over reusable manufacturing equipment are lower cost and simpler operation. And yet some processing steps, such as mixing, have not been able to realize these benefits. The Entegris mixing system is designed to maximize simplicity, ease-of-use, and affordability.

The Entegris microcarrier separation system is designed to ease the finance and complexity burdens of single-use systems while maximizing simplicity, ease of use, and affordability. This system facilitates a separation process through the use of a streamlined, single-use filter/mesh bag system and peristaltic pump; no other equipment is required.

Bringing the benefits of ultimate customization, fast design, and delivery to cell culture applications, Entegris offers the motion bioreactor bag.

What does “custom” mean for bioprocessing companies? Many system suppliers advertise their capability in customization but in reality, limit it to the interchange of components or lengths of tubing. This is helpful, but falls short of what many end users are looking for. With single-use systems, Entegris offers true customization to meet your exact process needs, fast.

CONTACT INFORMATION

Entegris, Inc.

129 Concord Road

Billerica, MA 01821

UNITED STATES

Phone: 978 436 6500

Fax: 978 436 6735

Contact: Barry Westfall

FEATURED ARTICLES

  • Advantages Of Single-Layer Film Vs. Multilayer Film In Bioprocessing

    Speed and flexibility are critical to succeed in the bioprocessing market. Plastics technology enables small-batch, single-use packaging solutions for customized drugs to serve a smaller patient population.

  • Employing Single-Use Technology To Control Frozen Bulk Drug Storage: The Cold Hard Facts

    The traditional approaches for primary packaging in frozen applications have been bottles and stainless steel cryo vessels. While each has its strengths, both have significant shortcomings. This paper addresses the challenges of bulk drug substance (BDS) storage, shipping, and other critical factors users must consider in deciding whether and how they will adopt the technology. Also highlighted are specific options to consider in moving toward single-use drug substance storage.

  • Cold-Chain Bioprocessing Readiness: Mitigating Risk And Protecting Pharmaceutical Products

    Many pharmaceuticals — monoclonal antibodies, vaccines, and patient-specific therapeutics — must be reliably stored and transported at sub-zero temperatures, requiring a robust cold chain that continues throughout downstream processing. This white paper addresses the concerns of development laboratories, contract manufacturing organizations (CMOs), and contract research organizations (CROs) and explains several factors they should consider when expanding operations and selecting single-use systems for cold-chain bioprocessing.

VIDEOS/WEBINARS